Serina Therapeutics, Inc.
SER · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.2% | 530.6% | -83.5% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -246.4% | 97.1% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -18,726.8% | 187.7% | -521% | -40.4% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -19,894.6% | 167.1% | -536.4% | -41.6% |
| EPS Diluted | -1.51 | 0.63 | -2.49 | -8.05 |
| % Growth | -339.7% | 125.3% | 69.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |